GEMMABio
GEMMABio is a Philadelphia-based biotech founded in 2024 by gene therapy pioneer Dr. James M. Wilson that develops next-generation AAV-based gene therapies for rare diseases, with lead programs in spinal muscular atrophy type 1 and Duchenne muscular dystrophy.
- Company typePrivate
- Founded2024
- HeadquartersPhiladelphia, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What GEMMABio does
GEMMABio is a Philadelphia-based biotechnology company founded in October 2024 by gene therapy pioneer Dr. James M. Wilson, focused on developing next-generation adeno-associated virus (AAV) based gene therapies for rare diseases. The company operates a portfolio of programs spanning motor neuron disorders (spinal muscular atrophy type 1 via lead asset GB221), skeletal and cardiac myopathies (Duchenne muscular dystrophy via GB703), and affiliated ultra-orphan disease work through its wholly owned spin-off Rare Therapeutics, Inc. (RareTx). Core technical differentiators include a novel myotropic AAV capsid (GCap104) for muscle-directed delivery, a de-immunized miniature utro/dystrophin hybrid transgene, and a modified SMN1 expression cassette delivered via intra-cisterna magna injection to reduce overexpression-related toxicity. Lead program GB221 is in the CHARISMA Phase 1/2 trial across U.S. and Brazilian sites, with GB703 currently in preclinical development and affiliated MVX-220 (Angelman syndrome) holding FDA Orphan Drug Designation.
The company is pre-revenue and clinical-stage. Anticipated revenue mechanics rely on one-time gene therapy product sales at premium pricing typical of rare disease AAV therapies (>$2M per treatment), supplemented by partnership milestone payments, royalties, and co-development arrangements. To date, GEMMABio has secured a $34M seed round (December 2024) co-led by Double Point Ventures, Bioluminescence Ventures, and Earlybird Venture Capital, plus a $100M strategic partnership with Brazil's Fiocruz for regional manufacturing and Latin American access. International expansion is further supported by UAE partnerships with the Department of Health – Abu Dhabi, M42, and PureHealth, positioning the company to pursue a multi-jurisdictional, emerging-market-enabled commercialization model that differentiates from U.S./EU-centric gene therapy peers.
GEMMABio firmographics
Firmographics- Name
- GEMMABio
- Legal name
- GEMMA Biotherapeutics
- Website
- https://gemmabiotx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GEMMABio is a Philadelphia-based biotech founded in 2024 by gene therapy pioneer Dr. James M. Wilson that develops next-generation AAV-based gene therapies for rare diseases, with lead programs in spinal muscular atrophy type 1 and Duchenne muscular dystrophy.
- Ownership category
- akta.pro rank
GEMMABio industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where GEMMABio is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
GEMMABio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Gene Therapy Product Sales: One-time gene therapy treatments for rare diseases. GEMMABio is developing transformative, next-generation AAV-based gene therapies delivered as single treatments. Revenue would be generated through product sales upon regulatory approval.
- Partnership and Licensing Agreements: Strategic partnerships with international entities such as the $100M agreement with Fiocruz for regional manufacturing and access expansion in Latin America. May include milestone payments, royalties, and co-development arrangements.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
GEMMABio product offering
Product offeringCore offering
GEMMABio develops next-generation AAV-based gene therapies for rare diseases, with clinical-stage programs for spinal muscular atrophy type 1 (GB221, currently in the CHARISMA Phase 1/2 trial in the U.S. and Brazil) and Duchenne muscular dystrophy (GB703, preclinical). The company designs engineered AAV capsids (GCap104), de-immunized transgenes, and innovative delivery methods (intra-cisterna magna injection) intended as transformative single-dose treatments, and partners with international organizations such as Fiocruz (Brazil) and UAE health authorities to enable local manufacturing and global access.
Product overview
GEMMABio is a biotechnology company developing a portfolio of gene therapies for rare diseases using next-generation AAV (adeno-associated virus) technology. The company's programs span motor neuron disorders and skeletal/cardiomyopathies. Core products include GB221 (clinical-stage gene therapy for SMA1, currently in CHARISMA Phase 1/2 trial), GB703 (preclinical gene therapy for DMD using a novel GCap104 capsid), and affiliated program MVX-220 (gene therapy for Angelman Syndrome). GEMMABio's platform is built on 40 years of AAV research led by founder Dr. James M. Wilson.
Differentiator
Problem solved
Functional benefit
Products and services
- GB221 Investigational next-generation AAV-based gene therapy for spinal muscular atrophy type 1 (SMA1). GB221 consists of an AAV vector encasing a codon-optimized SMN1 gene in a modified transgene expression cassette designed to reduce overexpression-related toxicities and sensory neurotoxicity. The therapy is delivered via intra-cisterna magna (ICM) injection into the cerebrospinal fluid to enable targeted motor neuron transduction without systemic toxicity, and is intended for pediatric SMA1 patients with high unmet medical need.
- GB703 Investigational AAV-based gene therapy for Duchenne muscular dystrophy (DMD). GB703 is designed to express a micro-utro/dystrophin hybrid gene in muscle cells using GEMMABio's proprietary myotropic AAV capsid (GCap104) and a de-immunized miniaturized transgene. It is delivered intravenously and engineered to provide broad mutation coverage across DMD patients, including those with N-terminal region deletions, and is intended as a single-dose transformative treatment for Duchenne muscular dystrophy.
Quantifiable outcome
- GB221 demonstrated over 50% survival at 120 days compared to under 15 days in untreated SMA1 models in preclinical studies.
- +1 more outcomes
Companies that use GEMMABio
Customer profileSegments1 record
Ideal customer profiles2 records
GEMMABio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GEMMABio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- Fiocruz (Oswaldo Cruz Foundation)flagship$100 million partnership agreement with Brazil's leading health research institute under the Ministry of Health. The partnership aims to expand research and access to gene therapies for rare diseases in Latin America, including local manufacturing capabilities and regional clinical trial operations. Brazil serves as a regional hub for GEMMABio's clinical activities.
- Department of Health - Abu DhabicoreRegulatory body of the Healthcare Sector in Abu Dhabi, UAE, partnering to advance gene therapies for children with spinal muscular atrophy and other rare diseases in the region.
- M42coreGlobal health champion headquartered in Abu Dhabi powered by AI, technology, and genomics to advance health innovation. Partnership focuses on collaborative efforts in gene therapy development and deployment.
- PureHealthcoreThe largest healthcare group in the UAE with expanding global operations, supporting GEMMABio's gene therapy access initiatives in the Middle East region.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
GEMMABio competitors and assessment
Company assessmentBroad incumbents
- Novartis (Zolgensma): Novartis commercializes Zolgensma, the first FDA-approved AAV gene therapy for SMA, which directly competes with GEMMABio's GB221 in SMA1. As a global pharmaceutical incumbent with established SMA commercial infrastructure, Novartis is the dominant comparator for any next-generation SMA1 gene therapy.
- BioMarin Pharmaceutical: BioMarin is an established rare disease biopharmaceutical company with a gene therapy pipeline (Roctavian for hemophilia A) and broader rare disease franchise. As a larger player with commercial infrastructure, BioMarin represents both a potential acquirer and competitive benchmark.
Direct peers
- Sarepta Therapeutics: Sarepta develops Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy, directly competing with GEMMABio's GB703 program. Both target DMD via AAV delivery of micro-dystrophin constructs, making Sarepta the most direct competitor in DMD gene therapy.
- Regenxbio: Regenxbio is a clinical-stage AAV gene therapy company developing treatments for rare diseases including SMA (RGX-202) and DMD, directly overlapping with GEMMABio's portfolio. Both companies leverage proprietary AAV capsid technologies developed within the broader AAV research community.
- uniQure: uniQure is a clinical-stage AAV gene therapy company with an approved product (Hemgenix for hemophilia B) and pipeline in rare diseases. Both companies share the AAV platform approach and target monogenic rare disease populations with one-time curative therapies.
- Solid Biosciences: Solid Biosciences develops AAV gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases, with programs in clinical development. Both companies target DMD via AAV micro-dystrophin delivery and share similar competitive dynamics.
- Rocket Pharmaceuticals: Rocket Pharmaceuticals develops AAV and lentiviral gene therapies for rare pediatric diseases including hematological and cardiac disorders. Both companies target ultra-rare pediatric populations with one-time gene therapy approaches.
Emerging players
- Passage Bio: Passage Bio is an AAV gene therapy company for rare CNS disorders that was founded by Dr. James Wilson and licensed technology from Penn's Gene Therapy Program — making it a closely related entity with shared scientific lineage. Both target CNS-delivered AAV gene therapies for rare pediatric diseases.
- Taysha Gene Therapies: Taysha is a clinical-stage AAV gene therapy company focused on rare CNS diseases. Both companies pursue AAV gene therapy for rare monogenic neurological disorders using similar delivery approaches and target similar patient populations.
- Krystal Biotech: Krystal Biotech commercializes Vyjuvek, an approved topical gene therapy for dystrophic epidermolysis bullosa (rare disease), and pursues additional rare disease programs. Krystal represents an emerging commercial-stage AAV gene therapy peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
GEMMABio social profiles
Digital presenceGEMMABio financial estimates
Financial estimateRevenue estimate
Valuation estimate
GEMMABio leadership team
Management profileNumber of profiles
Profiles6 records
GEMMABio subsidiaries and ownership
Company hierarchySubsidiaries1 record
GEMMABio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GEMMABio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GEMMABio
What does GEMMABio do?
GEMMABio develops next-generation AAV-based gene therapies for rare diseases, with clinical-stage programs for spinal muscular atrophy type 1 (GB221, currently in the CHARISMA Phase 1/2 trial in the U.S. and Brazil) and Duchenne muscular dystrophy (GB703, preclinical). The company designs engineered AAV capsids (GCap104), de-immunized transgenes, and innovative delivery methods (intra-cisterna magna injection) intended as transformative single-dose treatments, and partners with international organizations such as Fiocruz (Brazil) and UAE health authorities to enable local manufacturing and global access.
Is GEMMABio a public or private company?
GEMMABio is a private company. It is classified as venture growth investor backed and is currently operating.
When was GEMMABio founded?
GEMMABio was founded in 2024. It employs 51 to 100 people.
Where is GEMMABio based?
GEMMABio is headquartered in Philadelphia, United States, in the North America region.
How does GEMMABio make money?
Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are partnership and Licensing Agreements.
Who are GEMMABio's main competitors?
Broad incumbents on record are Novartis (Zolgensma) and BioMarin Pharmaceutical. Direct peers are Sarepta Therapeutics, Regenxbio, uniQure, Solid Biosciences and Rocket Pharmaceuticals. Emerging players are Passage Bio, Taysha Gene Therapies and Krystal Biotech.
Does GEMMABio have an API?
No public API is recorded for GEMMABio.
What industry is GEMMABio in?
GEMMABio's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2836.